Nivolumab Combination Therapy in Advanced Esophageal Squamous-Cell Carcinoma

Yuichiro Doki; Jaffer A. Ajani; Ken Kato; Jianming Xu; Lucjan Wyrwicz; Satoru Motoyama; Takashi Ogata; Hisato Kawakami; Chih-Hung Hsu; Antoine Adenis; Farid El Hajbi; Maria Di Bartolomeo; Maria I. Braghiroli; Eva Holtved; Sandra A Ostoich; Hye R. Kim; Masaki Ueno; Wasat Mansoor; Wen-Chi Yang; Tianshu Liu; John Bridgewater; Tomoki Makino; Ioannis Xynos; Xuan Liu; Ming Lei; Kaoru Kondo; Apurva Patel; Joseph Gricar; Ian Chau; Yuko Kitagawa

doi:10.1056/nejmoa2111380

Abstract

Both first-line treatment with nivolumab plus chemotherapy and first-line treatment with nivolumab plus ipilimumab resulted in significantly longer overall survival than chemotherapy alone in patients with advanced esophageal squamous-cell carcinoma, with no new safety signals identified. (Funded by Bristol Myers Squibb and Ono Pharmaceutical; CheckMate 648 ClinicalTrials.gov number, NCT03143153.).

Affiliated Institutions

Related Publications

Nivolumab plus Ipilimumab in Advanced Non–Small-Cell Lung Cancer

Matthew D. Hellmann , Luis Paz‐Ares , Reyes Bernabé +23 more

First-line treatment with nivolumab plus ipilimumab resulted in a longer duration of overall survival than did chemotherapy in patients with NSCLC, independent of the PD-L1 expr...

2019 New England Journal of Medicine 2696 citations

Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma

Robert J. Motzer , Nizar M. Tannir , Ray McDermott +29 more

Overall survival and objective response rates were significantly higher with nivolumab plus ipilimumab than with sunitinib among intermediate- and poor-risk patients with previo...

2018 New England Journal of Medicine 4403 citations

Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer

Julie R. Brahmer , Karen L. Reckamp , Paul Baas +22 more

Among patients with advanced, previously treated squamous-cell NSCLC, overall survival, response rate, and progression-free survival were significantly better with nivolumab tha...

2015 New England Journal of Medicine 8355 citations

Nivolumab plus Cabozantinib versus Sunitinib for Advanced Renal-Cell Carcinoma

Toni K. Choueiri , Thomas Powles , Mauricio Burotto +28 more

Nivolumab plus cabozantinib had significant benefits over sunitinib with respect to progression-free survival, overall survival, and likelihood of response in patients with prev...

2021 New England Journal of Medicine 1584 citations

Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma

Jedd D. Wolchok , Vanna Chiarion‐Sileni , René González +30 more

Among patients with advanced melanoma, significantly longer overall survival occurred with combination therapy with nivolumab plus ipilimumab or with nivolumab alone than with i...

2017 New England Journal of Medicine 5260 citations

Publication Info

Year: 2022
Type: article
Volume: 386
Issue: 5
Pages: 449-462
Citations: 1053
Access: Closed

External Links

View on DOI.org

Social Impact

Altmetric

Nivolumab Combination Therapy in Advanced Esophageal Squamous-Cell Carcinoma

PlumX Metrics

Social media, news, blog, policy document mentions

Citation Metrics

1053

OpenAlex

Cite This

APA Style

                            
                                
                                    Yuichiro Doki, 
                                
                                    Jaffer A. Ajani, 
                                
                                    Ken Kato
                                
                                et al.
                            
                            (2022). 
                            Nivolumab Combination Therapy in Advanced Esophageal Squamous-Cell Carcinoma. 
                            New England Journal of Medicine
                            , 386
                            (5)
                            , 449-462.
                            https://doi.org/10.1056/nejmoa2111380
                        

Identifiers

DOI: 10.1056/nejmoa2111380